**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Presently amended) A compound having the chemical formula:




wherein $R_1$ is selected from the group consisting of: heteroaryl and heterocycloalk;

$R_2$ is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =O. C(O)OH, C(O)O-lower alk, C(O)NH-lower alk, C(O)N(lower alk)$_2$, SH, S-lower alk, $NH_2$, NH-lower alk, and N(lower alk)$_2$,

$R_3$ and $R_4$ is each independently lower alk or together cyclopropyl;

$R_5$ is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a *meta* or *para* position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy,

provided that said substituted phenyl may also have 2 to 3 additional substituents;

$R_6$ if present is either hydrogen, lower alkyl or lower alkenyl, wherein $R_6$ is not present if $R_2$ is =O;

$Y_1$ is either covalent bond, alkylene, or alkenylene;

$Y_2$ is alkylene;

$Y_3$ is alkylene;

Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene,

provided that $R_1$ is not pyridyl, benzydioxy, or thiophene;

provided that if Z is either O, S, NH, or N-lower alk, then $Y_1$ is not a covalent bond; further provided that $Y_1$ and Z may together be a covalent bond;

further provided that if $R_5$ is 3, 4 dimethoxy-phenyl, then $R_1$ is not ~~$CH_3(CH_2)_5O$ phenyl; 2-cyclopentyl, phenyl; 2-Cl-phenyl; 2-CN phenyl; 2-(3-furanyl)phenyl; or~~ 4-benzo(d)isothiazole;

further provided that if $R_5$ is 4-methoxy-phenyl, then $R_1$ is not ~~2-cyclopentyl-phenyl; 2-$CH_3$-phenyl; 2-benzyl phenyl; 3-$CH_3$-phenyl, 4-$CH_3SO_2$-phenyl,~~ 4-benzo(d)isothiazole;

further provided that if $R_5$ is 4-Cl-phenyl, then $R_1$ is not ~~2-$CH_3$-phenyl, 5-iso-propyl-phenyl; 4-$CH_3$-phenyl; phenyl; 2-Cl phenyl; 4-Cl phenyl; 2-methoxy, 4-$CH_3CHCH$-phenyl; 3,4-$CH_3$-phenyl, 2,4-$CH_3$-phenyl; 2,3-$CH_3$-phenyl; 2-iso-propyl, 5-$CH_3$-phenyl;~~ pyridyl; 1-imidazole; or 4-benzo(d)isothiazole; and

~~further provided that if $R_5$ is 3,5-dimethyl, 4-methoxy-phenyl, then $R_1$ is not 4-$CH_3$, 6-CN-2-pyridyl, 3-CN-pyridyl; and~~

pharmaceutically acceptable salts and complexes thereof;

wherein said compound has an $IC_{50} \leq 10$ μM using the Calcium Receptor Inhibitor Assay.

2. (Original) The compound of claim 1, wherein:

$Y_1$ is methylene;

$Y_2$ is methylene; and

$Y_3$ is methylene.

3. (Original) The compound of any of claims 1-2, wherein

$R_2$ is OH or methoxy,

$R_6$ is hydrogen,

$R_3$ or $R_4$ is independently methyl or ethyl; and

Z is O, S, or unsubstituted alkylene.

4. (Original) The compound of claim 3, wherein $R_2$ is OH, and Z is O.

5. (Original) The compound of claims 1-2, wherein

$R_2$ is hydrogen,

$R_6$ is hydrogen,

$R_3$ and $R_4$ is independently methyl or ethyl; and

Z is O or methylene.

6. (Presently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claims ~~1-3~~ 1-2.

7-31 (Withdrawn - list)

32. (New) The compound of claim 1 wherein $R_1$ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinolinyl, isoquinolinyl; and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower

haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, $NO_2$, $NH_2$, and OH.

33. (New) The compound of claim 3 wherein $R_1$ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinolinyl, isoquinolinyl, and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, $NO_2$, $NH_2$, and OH.

34. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 3.

35. (New) A compound having the chemical formula:




wherein $R_1$ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinolinyl, isoquinolinyl, and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, $NO_2$, $NH_2$, and OH;

$R_2$ is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =O. C(O)OH, C(O)O-lower alk, C(O)NH-lower alk, C(O)N(lower alk)$_2$, SH, S-lower alk, $NH_2$, NH-lower alk, and N(lower alk)$_2$,

$R_3$ and $R_4$ is each independently lower alk or together cyclopropyl;

$R_5$ is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a *meta* or *para* position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, provided that said substituted phenyl may also have 2 to 3 additional substituents;

$R_6$ if present is either hydrogen, lower alkyl or lower alkenyl, wherein $R_6$ is not present if $R_2$ is =O;

$Y_1$ is either covalent bond, alkylene, or alkenylene;

$Y_2$ is alkylene;

$Y_3$ is alkylene;

Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either O, S, NH, or N-lower alk, then $Y_1$ is not a covalent bond; further provided that $Y_1$ and Z may together be a covalent bond; and

pharmaceutically acceptable salts and complexes thereof;

wherein said compound has an $IC_{50} \leq 10$ μM using the Calcium Receptor Inhibitor Assay.

36. (New) The compound of claim 35, wherein:

$Y_1$ is methylene;

$Y_2$ is methylene; and

$Y_3$ is methylene.

37. (New) The compound of any of claims 34-35, wherein

$R_2$ is OH or methoxy,

$R_6$ is hydrogen,

$R_3$ or $R_4$ is independently methyl or ethyl; and

Z is O, S, or unsubstituted alkylene.

38. (New) The compound of claim 36, wherein $R_2$ is OH, and Z is O.

39. (New) The compound of claims 34-35, wherein

$R_2$ is hydrogen,

$R_6$ is hydrogen,

$R_3$ and $R_4$ is independently methyl or ethyl; and

Z is O or methylene.

40. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claims 34-35.